Results 211 to 220 of about 21,078 (260)

GALANTHAMINE AND CEREBRAL PALSY

Lancet, The, 1963
exaly   +2 more sources

Galanthamine treatment in Alzheimer’s disease

1991
18 patients who had fulfilled the NINCDS-ADRDA criteria for "possible AD" took part in a clinical study to evaluate the effect of the cholinesterase inhibitor Galanthamine, 30 mg/day. Neuropsychological und social parameters were rated. This open clinical pilot-study showed no statistic significant change in neuropsychological test-results.
P, Dal-Bianco, J, Maly, C, Wôber, C, Lind, G, Koch, J, Hufgard, I, Marschall, M, Mraz, L, Deecke   +8 more
openaire   +2 more sources

Syntheses of (‐)‐Galanthamine

ChemInform, 2004
AbstractFor Abstract see ChemInform Abstract in Full Text.
openaire   +1 more source

Zur Epimerisierung von Galanthamin

Chemische Berichte, 1964
AbstractDas kürzlich als 2‐Hydroxy‐4.5‐epoxy‐6‐O‐methyl‐tetrahydro‐apogalanthamin beschriebene Abbauprodukt aus Galanthamin wurde als (–)‐Epigalanthamin identifiziert.
Gert P. Volpp, Lilia Bubewa‐Iwanowa
openaire   +1 more source

Wege zu (‐)‐Galanthamin

Nachrichten aus der Chemie, 2004
AbstractEine Zielstruktur, zwei Blickwinkel. Für Forscher aus Industrie und Hochschule zeigt sich die Totalsynthese des Anti‐Alzheimer‐Medikaments (‐)‐Galanthamin ganz unterschiedlich.
openaire   +1 more source

Cholinesterase inhibition by galanthamine and lycoramine

Biochemical Pharmacology, 1960
Abstract Galanthamine, a recently isolated alkaloid, has been found to inhibit the acetylcholinesterase of muscle and the cholinesterase of plasma and brain. The inhibition of the muscle enzyme by galanthamine is greater than that produced by pyridostigmin, a compound of known usefulness, but less than that of neostigmin.
R L, IRWIN, H J, SMITH
openaire   +2 more sources

Microbial transformations of galanthamin-precursors

Applied Microbiology and Biotechnology, 1986
Galanthamin is a medical important alkaloid. Its chemical synthesis gives a racemic product in low yields. Starting with a belladinderivative an enzymatic ring closure should lead exclusively to a chiral product possibly with the native structure. Although this reactions type is unknown in preparative biotransformations a large number of microorganisms
G. Spassov, W.R. Abraham, K. Kieslich, R. Vlahov, D. Krikozian, St. Parushev, M. Chinova, G. Snatzke   +7 more
openaire   +1 more source

Total Synthesis of (.+‐.)‐Galanthamine (I).

ChemInform, 2006
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
Xiang‐Dong Hu, Yong Qiang Tu, En Zhang, Shuanhu Gao, Shaohua Wang, Aixia Wang, Chun‐An Fan, Min Wang   +7 more
openaire   +1 more source

Facile synthesis of (±)‐, (+)‐, and (‐)‐galanthamine

Journal of Heterocyclic Chemistry, 1995
AbstractThe Amarylidacea alkaloid galanthamine (1a) is an acetylcholinesterase inhibitor that has been evaluated as a potential agent for the treatment of Alzheimer's disease. We report a very efficent synthesis of (±)‐galanthamine [(±)‐1a] from readily available isovanillin and tyramine.
Jerzy Szewczyk, Joseph W. Wilson, Anita H. Lewin, F. Ivy Carroll   +3 more
openaire   +1 more source

Galanthamine.

JAMA, 1978
D A, Cozanitis, E, Toivakka
openaire   +3 more sources